Amarin Corp Plc (AMRN)

[sstyles]

I think China could be worth quite a lot.

The press release said:

There were approximately 180.4 million hypertriglyceridemia (HTG) patients in China in 2019, representing approximately 20.2% of the adult population. Among all HTG patients in China, there were approximately 9 million adults who had very high TG levels (≥500 mg/dL). In 2019, there were approximately 36.1 million statin-treated adult patients in China with elevated TG levels (≥150 mg/dL) and either established CVD or diabetes mellitus and two or more additional risk factors for CVD, the addressable patients of the FDA-approved indication for reducing CV events of VASCEPA in China.

A previous press release said a royalty in the high teens. Let's say 15% to be conservative. And if it's 18% or 19% royalty even better.

Let's say 20mm people are on Vascepa in China times 15% royalty times price of Vascepa in China and you are looking at staggering numbers. Remember this is a volume play and fortunately Vascepa is not a high priced drug.

Even if it's only 10 mm people you are still looking at staggering numbers.

China is quite valuable and remember we are working with a local partner. Best way to do business over there. Cardiovascular disease is a high priority in China.

JMO